Zilver PTX (Cook Medical) shows positive data at 4 years in PAD trial

Four-year data from a trial of the Zilver PTX paclitaxel-eluting stent, from Cook Medical, for Femoropopliteal Disease, demonstrates 75% primary patency in the superficial femoral artery (SFA) at four years. This compares to 57.9% patency for patients with provisional bare metal stent placement in the study, a 41% reduction in four-year restenosis with the paclitaxel coating in the head-to-head comparison of provisional paclitaxel-eluting stent placement versus BMS placement.

The data shows that 83.2% of patients with femoropopliteal lesions who were treated with Zilver PTX did not require revascularization after four years. In comparison, 69.4% of patients treated with acutely successful percutaneous transluminal angioplasty (PTA) or provisional BMS placement did not require revascularization. Results were presented at the 2013 Vascular Interventional Advances (VIVA) meeting.